VK2735 reportedly helped maintain weight loss in a trial, even with once-a-month dosing
MarketWatch reports that Viking Therapeutics is developing the GLP-1/GIP drug, which could compete with Eli Lilly’s Zepbound.
TLDR
MarketWatch reports that Viking Therapeutics’ VK2735 helped people maintain their weight loss in a clinical trial, including participants taking it once a month. The outlet describes the GLP-1/GIP drug, still in development, as a potential competitor to Eli Lilly’s Zepbound.
Combined views
47K
2 Sources, first seen ago